Prevalence of undiagnosed atrial fibrillation and of that not being treated with anticoagulant drugs: the AFABE study.
OBJECTIVE
Atrial fibrillation constitutes a serious public health problem because it can lead to complications. Thus, the management of this arrhythmia must include not only its treatment, but antithrombotic therapy as well. The main goal is to determine the proportion of cases of undiagnosed atrial fibrillation and the proportion of patients not being treated with oral anticoagulants.


METHODS
A multicenter, population-based, retrospective, cross-sectional, observational study. In all, 1043 participants over 60 years of age were randomly selected to undergo an electrocardiogram in a prearranged appointment. Demographic data, CHA2DS2-VASc and HAS-BLED scores, international normalized ratio results, and reasons for not receiving oral anticoagulant therapy were recorded.


RESULTS
The overall prevalence of atrial fibrillation was 10.9% (95% confidence interval, 9.1%-12.8%), 20.1% of which had not been diagnosed previously. In the group with known atrial fibrillation, 23.5% of those with CHA2DS2-VASc≥2 were not receiving oral anticoagulant therapy, and 47.9% had a HAS-BLED score≥3. The odds ratio for not being treated with oral anticoagulation was 2.04 (95% confidence interval, 1.11-3.77) for women, 1.10 (95% confidence interval, 1.05-1.15) for more advanced age at diagnosis, and 8.61 (95% confidence interval 2.38-31.0) for a CHA2DS2-VASc score<2. Cognitive impairment (15.2%) was the main reason for not receiving oral anticoagulant therapy.


CONCLUSIONS
The prevalence of previously undiagnosed atrial fibrillation in individuals over 60 years of age is 20.1%, and 23.5% of those who have been diagnosed receive no treatment with oral anticoagulants.
Atención Primaria/Hospitalaria, Institut Català de la Salut, Gerència Territorial Terres de l'Ebre, Tortosa, Tarragona, Spain. Electronic address: jlclua.ebre.ics@gencat.cat.
Josep L
JL
Clua-Espuny
Atención Primaria/Hospitalaria, Institut Català de la Salut, Gerència Territorial Terres de l'Ebre, Tortosa, Tarragona, Spain.
Iñigo
I
Lechuga-Duran
USR Terres de l'Ebre, IDIAP Jordi Gol-IISPV-Fundació Dr. Ferran, Tortosa, Tarragona, Spain.
Ramón
R
Bosch-Princep
USR Terres de l'Ebre, IDIAP Jordi Gol-IISPV-Fundació Dr. Ferran, Tortosa, Tarragona, Spain.
Albert
A
Roso-Llorach
Atención Primaria/Hospitalaria, Institut Català de la Salut, Gerència Territorial Terres de l'Ebre, Tortosa, Tarragona, Spain.
Anna
A
Panisello-Tafalla
Atención Primaria/Hospitalaria, Institut Català de la Salut, Gerència Territorial Terres de l'Ebre, Tortosa, Tarragona, Spain.
Jorgina
J
Lucas-Noll
USR Terres de l'Ebre, IDIAP Jordi Gol-IISPV-Fundació Dr. Ferran, Tortosa, Tarragona, Spain.
Carles
C
López-Pablo
Atención Primaria/Hospitalaria, Institut Català de la Salut, Gerència Territorial Terres de l'Ebre, Tortosa, Tarragona, Spain.
Lluïsa
L
Queralt-Tomas
Economía de la Salut, Antares Consulting, Barcelona, Spain.
Emmanuel
E
Giménez-Garcia
Economía de la Salud, Boehringer-Ingelheim España, Sant Cugat del Vallès, Barcelona, Spain.
Núria
N
González-Rojas
Pla Director de la Malaltia Vascular Cerebral de Catalunya, Departament de Salut, Generalitat de Catalunya, Barcelona, Spain.
Miquel
M
Gallofré López
D000368:Aged; D000925:Anticoagulants / Q000627:therapeutic use*; D001281:Atrial Fibrillation / Q000175:diagnosis* / Q000188:drug therapy / Q000453:epidemiology*; D003430:Cross-Sectional Studies; D004562:Electrocardiography; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D015995:Prevalence; D012189:Retrospective Studies; D013030:Spain / Q000453:epidemiology
D000925:Anticoagulants
AF; Anticoagulation for atrial fibrillation; Atrial fibrillation; CHA(2)DS(2)-VASc; Estudio de base poblacional; Fibrilación auricular; HAS-BLED; INR; OAT; Population-based study; Prevalence; Prevalencia; Tratamiento anticoagulante; atrial fibrillation; congestive heart failure, hypertension, age≥75 (doubled), diabetes, stroke (doubled)-vascular disease and sex category (female); hypertension, abnormal renal/liver function, stroke, bleeding history or predisposition, labile international normalized ratio, elderly (>65 years), drugs/alcohol concomitantly; international normalized ratio; oral anticoagulant therapy